Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2205-2209

  Söling, Ariane ^a   Schurr, Peter ^a   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

MAGE; Neuroblastoma; NY ESO 1

Indexed keywords

ANTIGEN; FERRITIN; VANILMANDELIC ACID;

ANTIGEN EXPRESSION; ARTICLE; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINE LEVEL;

ADULT; AGE FACTORS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; FERRITINS; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEUROBLASTOMA; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VANILMANDELIC ACID;

EID: 0032781746     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. van der Bruggen P, Traversari C, Chomez P et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-47, 1991.
2. Van den Eynde B and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-93, 1997.
3. Sahin U, Türeci Ö, Schmitt H et al: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci 92: 11810-13, 1995.
4. Chen YT, Scanlan MJ, Sahin U et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci 94: 1914-18, 1997.
5. Brasseur F, Rimoldi D, Lienard D et al: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63: 375-80, 1995.
6. Weynants P, Lethe B, Brasseur F et al: Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 56: 826-29, 1994.
7. Brasseur F, Marchand M, Vanwijck R et al: Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 52: 839-41, 1992.
8. Yamada A, Kataoka A, Shichijo S et al: Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 64: 388-93, 1995.
9. Inoue H, Mori M, Honda M et al: Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 63: 523-26, 1995.
10. Jäger E, Chen YT, Drijfhout JW et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human hislocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-70, 1998.
11. van der Bruggen P, Szikora JP, Boël P et al: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw 1601. Eur J Immunol 24: 2134-40, 1994.
12. Gaugler B, Van den Ende B, van der Bruggen P et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921-30, 1994.
13. Wang RF, Johnston SL, Zeng G et al: A breast and melanoma-shared antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161: 3596-06, 1998.
14. van der Bruggen P, Bastin J, Gajewski T et al: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038-43, 1994.
15. Herman J, van der Bruggen P, Luescher IF et al: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43: 377-83, 1996.
16. Traversari C, van der Bruggen P, Luescher IF et al: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med 176: 1453-57, 1992.
17. Marchand M, Weynants P, Rankin E et al: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int J Cancer 63: 883-85, 1995.
18. Hoon DS, Yuzuki D, Hayashida M and Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody response to recombinant MAGE-1 antigen. J Immunol 154: 730-37, 1995.
19. Hu X, Chakraborty NG, Sporn JR et al: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56: 2479-83, 1996.
20. Reynolds SR, Oratz R, Shapiro RL et al. Stimulation of CD8+ T cell responses to MAGE-3 and MELAN A/ MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72: 972-76, 1997.
21. Corrias MV, Scaruffi P, Occhino M et al: Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer (Pred. Oncol.) 69: 403-07, 1996.
22. Ishida H, Matsumura T, Salgaller ML et al: MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer (Pred Oncol) 69: 375-80, 1996.
23. Cheung IY, Barber D and Cheung NKV. Detection of microscopic neuroblastoma in marrow by histology, immunocytology and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 4: 2801-05, 1998.
24. Chen RL, Hong CM, Peters J et al: Frequent expression of MAGE and BAGE genes by neuroblastomas. Advances in Neuroblastoma Research A23, 1996.
25. Maeurer MJ, Storkus WJ, Kirkwood JM et al: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6: 11-24, 1996.
26. Hughes M, Marsden HB and Palmer MK. Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 34: 1706-11, 1974.
27. Lethi B, van der Bruggen P, Brasseur F and Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 7: S83-S88, 1997.
28. Marchand M, Van Baren N, Weynants P et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219-230, 1999.
29. Zuber M, Spagnoli GC, Kocher T et al: Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Eur Surg Res 29: 403-10, 1997.
30. 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res 45: 5976-80, 1985.
31. Blankenstein T, Cayeux S and Qin Z. Genetic approaches to cancer immunotherapy. Rev Physiol Biochem Pharmacol 129: 1-49, 1996.